BofA downgraded AMN Healthcare to Underperform from Neutral with a price target of $48, down from $65. The firm is lowering 2025-2026 EBITDA estimates to reflect the lower Q4 exit rate and its multiple given the downside risk it sees to estimates. The firm sees uncertainty to temporary nurse demand as the slowing economy could create added pressure, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN: